NNC0519-0130 clinical trials
Also written NNC0519-0130.
How each study uses NNC0519-0130 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the NNC0519-0130 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- NNC0519-0130
- 10
Studies by the year they started
11 studies that test it; most in 2024 (8)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 8 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses NNC0519-0130 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney DiseaseRecruitingPhase 2Novo Nordisk A/SNCT06717698Written as NNC0519-0130
- A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 DiabetesCompletedPhase 2Novo Nordisk A/SNCT06326047Written as NNC0519-0130
- A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose WeightCompletedPhase 2Novo Nordisk A/SNCT06326060Written as NNC0519-0130
- A Research Study Looking Into Blood Levels of the Medicine NNC0519-0130 in the Body in Participants With Normal or Reduced Kidney FunctionCompletedPhase 1Novo Nordisk A/SNCT06370819Written as NNC0519-0130
- A Research Study Comparing Different Ways of Increasing the Dose of NNC0519-0130 in Participants With Overweight or ObesityCompletedPhase 1Novo Nordisk A/SNCT06718998Written as NNC0519-0130
- A Research Study of the New Medicine NNC0519-0130 in Male Chinese Participants Living With Excess Body WeightCompletedPhase 1Novo Nordisk A/SNCT07004322Written as NNC0519-0130
- A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After MenopauseCompletedPhase 1Novo Nordisk A/SNCT06513104Written as NNC0519-0130
- A Research Study of a New Medicine NNC0519-0130 in Healthy People, People With High Body Weight and People With Type 2 Diabetes.CompletedPhase 1Novo Nordisk A/SNCT05363774Written as NNC0519-0130
- A Research Study of How Safe a New Medicine Called NNC0519 0130 is and to Test Its Effect in People Living With Excess Body Weight With or Without Type 2 DiabetesCompletedPhase 1Novo Nordisk A/SNCT06567041Written as NNC0519-0130
- A Research Study to Compare How Much of the Medicine NNC0519-0130 is in the Blood of People With Overweight or Obesity Who Receive 2 Preparations of the MedicineCompletedPhase 1Novo Nordisk A/SNCT06642571Written as NNC0519-0130 B
- A Research Study of a New Medicine NNC0519-0130 in Japanese and Non-Japanese MenCompletedPhase 1Novo Nordisk A/SNCT05870670Written as NNC0519-0130